Angela Rizk-Jackson
Research Subjects
Angela Rizk-Jackson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Clifford Jack
Mayo Alzheimer's Disease Research Center, Rochester, Minnesota, United States of America
1 shared publicationMichael Weiner
Center for Imaging of Neurodegenerative Disease, Veterans Administration Medical Center, San Francisco, California, United States of America
1 shared publicationPaul Aisen
Alzheimer's Disease Cooperative Study, University of California, San Diego, La Jolla, California, United States of America
1 shared publicationPhilip Insel
Center for Imaging of Neurodegenerative Disease, Veterans Administration Medical Center, San Francisco, California, United States of America
1 shared publicationRonald Petersen
Mayo Alzheimer's Disease Research Center, Rochester, Minnesota, United States of America
1 shared publication
Latest Publications
- Open Access
- 9 September 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e74062
Early Indications of Future Cognitive Decline: Stable versus Declining Controls
This study aimed to identify baseline features of normal subjects that are associated with subsequent cognitive decline. Publicly available data from the Alzheimer’s Disease Neuroimaging Initiative was used to find differences in baseline clinical assessments (ADAScog, AVLT, FAQ) between cognitively healthy individuals who will suffer cognitive decline within 48 months and those who will remain stable for that period. Linear regression models indicated an individual’s conversion status was significantly associated with certain baseline neuroimaging measures, including posterior cingulate glucose metabolism. Linear Discriminant Analysis models built with baseline features derived from MRI and FDG-PET measures were capable of successfully predicting whether an individual will convert to MCI within 48 months or remain cognitively stable. The findings from this study support the idea that there exist informative differences between normal people who will later develop cognitive impairments and those who will remain cognitively stable for up to four years. Further, the feasibility of developing predictive models that can detect early states of cognitive decline in seemingly normal individuals was demonstrated.
- 9 September 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e74062
Open AccessEarly Indications of Future Cognitive Decline: Stable versus Declining Controls
This study aimed to identify baseline features of normal subjects that are associated with subsequent cognitive decline. Publicly available data from the Alzheimer’s Disease Neuroimaging Initiative was used to find differences in baseline clinical assessments (ADAScog, AVLT, FAQ) between cognitively healthy individuals who will suffer cognitive decline within 48 months and those who will remain stable for that period. Linear regression models indicated an individual’s conversion status was significantly associated with certain baseline neuroimaging measures, including posterior cingulate glucose metabolism. Linear Discriminant Analysis models built with baseline features derived from MRI and FDG-PET measures were capable of successfully predicting whether an individual will convert to MCI within 48 months or remain cognitively stable. The findings from this study support the idea that there exist informative differences between normal people who will later develop cognitive impairments and those who will remain cognitively stable for up to four years. Further, the feasibility of developing predictive models that can detect early states of cognitive decline in seemingly normal individuals was demonstrated.